Lumina Pharmaceuticals uses radioligand therapy to target biomarkers that are abundantly present in various disease states yet largely absent in healthy humans.
Choose the isotope—diagnostic or therapeutic—and attach it to our solid tumor seeking peptide
The compound targets and binds selectively within the tumor’s extracellular matrix
The diagnostic radioisotope visualizes the tumor, de-risking treatment
The therapeutic radioisotope releases localized radiation to kill the cancer cells
Lumina’s lead asset targets fibrin, which is abundant in the microenvironment of solid tumors and absent in healthy tissue. Our fibrin targeting approach has been recently validated in human imaging and mouse studies.
Found in tumors, not healthy cells
Found throughout solid tumors within the extracellular matrix (ECM)
Consistently appear in large quantities across multiple types of solid cancer tumors
We are building a pipeline of theranostic assets to address unmet need in cancer.
Additionally, Lumina has clinical stage PET imaging agents for non-oncology applications in detecting and monitoring fibrosis and thrombus (clot).
Novel, first-in-class radiopharmaceutical targeting a hallmark of the solid tumor microenvironment December 22, 2025, Boston, MA – Lumina Pharmaceuticals, a clinical-stage radiopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)
December 1, 2025: Lumina Pharmaceuticals, a clinical stage company developing radiopharmaceuticals, announced today that industry expert Eric S. Hoffman, Ph.D., will join the company as Chief Business Officer. In this role, Dr. Hoffman
